|
(Health-NewsWire.Net, April 30, 2015 ) Global Markets Direct’s, ‘Metastatic Ovarian Cancer – Pipeline Review, H1 2015′, provides an overview of the Metastatic Ovarian Cancer’s therapeutic pipeline. Metastatic cancer is a cancer that has spread from the primary site of the body where it started to other parts of the body. Treatment is also based on where the cancer started.
This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Complete report on H1 2015 pipeline review of “Metastatic Ovarian Cancer” addiction with 25 market data tables and 13 figures, spread across 65 pages is available at http://www.rnrmarketresearch.com/metastatic-ovarian-cancer-pipeline-review-h1-2015-market-report.html . (This is a premium report price at US$2000 for a single user PDF license)
The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Scope:
• The report provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Metastatic Ovarian Cancer and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Metastatic Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=375212 .
Reasons to Buy:
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Metastatic Ovarian Cancer
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer pipeline depth and focus of Indication therapeutics
More reports on Cancer Therapeutics :
Global Melanoma Therapeutics Market 2015-2019
According to Melanoma Research Foundation, melanoma is usually, but not always, a cancer of the skin. Melanoma is defined as a cancer that occurs in melanocytes (cells that make the pigment melanin). Chest and back in men and legs in women are the most likely parts to be affected with melanoma. CM, MM, and OM are the three major categories of melanoma. The exact etiology of melanoma is unknown. According to the American Skin Association, the incidence of melanoma is increasing worldwide. The median age of diagnosis is 59 years and the median age of death due to melanoma is 67 years.
Complete report is available at http://www.rnrmarketresearch.com/global-melanoma-therapeutics-market-2015-2019-market-report.html .
RnR Market Research
Ritesh Tiwari
+ 1 888 391 5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
